Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
29 Jan 2019

Salvage treatment with carfilzomib, pomalidomide and dexamethasone (KPd) is effective and safe in transplant-eligible multiple myeloma (MM) patients with refractory disease or first progression on or after treatment with bortezomib and lenalidomide, according to data from patients enrolled in the EMN02 trial.

Cancer progression common in men who undergo deferred prostatectomy

11 Sep 2018
Prostate cancer is a silent killer. Many may not be aware of the illness until it is too late.

Despite active surveillance, cancer progression appears to be common in men who undergo deferred radical prostatectomy (RP), according to a recent study.

The study included 132 men with screening-detected prostate cancer (median age 64 years) who received radical prostatectomy following active surveillance. Radical prostatectomy was performed upon detection of disease progression or patient request. Active surveillance included prostate-specific antigen (PSA) tests every 3–6 months and biopsies every 2–4 years.

The median time from prostate cancer diagnosis to RP was 1.9 years, during which the participants received a median of one repeat biopsy for active surveillance.

At deferred RP, 52 patients (39 percent) showed at least one unfavourable pathology in the RP specimen. For instance, 35 percent (n=46) of the participants demonstrated an increase in Gleason score (GS) from diagnostic biopsy. Twelve men (9.1 percent) had GS >3+4.

Moreover, 22 percent (n=29) were positive for extraprostatic extensions, 3.0 percent (n=4) had seminal vesicle invasion, 22 percent (n=29) demonstrated positive surgical margins, and 0.8 percent (n=1) had positive lymph nodes. The median tumour volume was 0.70 mL.

PSA relapse was reported in 25 men, 10 of whom underwent salvage radiation. The resulting 10-year PSA relapse-free survival was 79.5 percent.

At the time of diagnostic biopsy, 29 percent (n=38) of the patients had unidentifiable index tumours. At the last repeat biopsy before the deferred surgery, index tumour was not identified in 22 participants (21 percent).

Clinicians can use the findings in counselling prostate cancer patients who choose to undergo active surveillance and deferred RP, researchers said, adding that there is a need to improve the detection of cancer progression during active surveillance.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
29 Jan 2019

Salvage treatment with carfilzomib, pomalidomide and dexamethasone (KPd) is effective and safe in transplant-eligible multiple myeloma (MM) patients with refractory disease or first progression on or after treatment with bortezomib and lenalidomide, according to data from patients enrolled in the EMN02 trial.